183 related articles for article (PubMed ID: 9815950)
1. Pilot radioimmunotherapy trial with 131I-labeled murine monoclonal antibody CC49 and deoxyspergualin in metastatic colon carcinoma.
Divgi CR; Scott AM; Gulec S; Broussard EK; Levy N; Young C; Capitelli P; Daghighian F; Williams JM; Finn RD
Clin Cancer Res; 1995 Dec; 1(12):1503-10. PubMed ID: 9815950
[TBL] [Abstract][Full Text] [Related]
2. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma.
Divgi CR; Scott AM; Dantis L; Capitelli P; Siler K; Hilton S; Finn RD; Kemeny N; Kelsen D; Kostakoglu L
J Nucl Med; 1995 Apr; 36(4):586-92. PubMed ID: 7699446
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer.
Welt S; Divgi CR; Kemeny N; Finn RD; Scott AM; Graham M; Germain JS; Richards EC; Larson SM; Oettgen HF
J Clin Oncol; 1994 Aug; 12(8):1561-71. PubMed ID: 8040668
[TBL] [Abstract][Full Text] [Related]
4. Fractionated radioimmunotherapy of human colon carcinoma xenografts with 131I-labeled monoclonal antibody CC49.
Buchsbaum D; Khazaeli MB; Liu T; Bright S; Richardson K; Jones M; Meredith R
Cancer Res; 1995 Dec; 55(23 Suppl):5881s-5887s. PubMed ID: 7493364
[TBL] [Abstract][Full Text] [Related]
5. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma.
Mulligan T; Carrasquillo JA; Chung Y; Milenic DE; Schlom J; Feuerstein I; Paik C; Perentesis P; Reynolds J; Curt G
Clin Cancer Res; 1995 Dec; 1(12):1447-54. PubMed ID: 9815943
[TBL] [Abstract][Full Text] [Related]
7. Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial.
Macey DJ; Grant EJ; Kasi L; Rosenblum MG; Zhang HZ; Katz RL; Rieger PT; LeBherz D; South M; Greiner JW; Schlom J; Podoloff DA; Murray JL
Clin Cancer Res; 1997 Sep; 3(9):1547-55. PubMed ID: 9815842
[TBL] [Abstract][Full Text] [Related]
8. A novel monoclonal antibody design for radioimmunotherapy.
Forero A; Meredith RF; Khazaeli MB; Carpenter DM; Shen S; Thornton J; Schlom J; LoBuglio AF
Cancer Biother Radiopharm; 2003 Oct; 18(5):751-9. PubMed ID: 14629823
[TBL] [Abstract][Full Text] [Related]
9. Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct.
Pavlinkova G; Booth BJ; Batra SK; Colcher D
Clin Cancer Res; 1999 Sep; 5(9):2613-9. PubMed ID: 10499640
[TBL] [Abstract][Full Text] [Related]
10. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma.
Divgi CR; Bander NH; Scott AM; O'Donoghue JA; Sgouros G; Welt S; Finn RD; Morrissey F; Capitelli P; Williams JM; Deland D; Nakhre A; Oosterwijk E; Gulec S; Graham MC; Larson SM; Old LJ
Clin Cancer Res; 1998 Nov; 4(11):2729-39. PubMed ID: 9829736
[TBL] [Abstract][Full Text] [Related]
11. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
Wong JY; Chu DZ; Yamauchi D; Odom-Maryon TL; Williams LE; Liu A; Esteban JM; Wu AM; Primus FJ; Beatty JD; Shively JE; Raubitschek AA
J Nucl Med; 1998 Dec; 39(12):2097-104. PubMed ID: 9867150
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II trial of combined 131I anti-CEA monoclonal antibody and hyperthermia in patients with advanced colorectal adenocarcinoma.
Mittal BB; Zimmer MA; Sathiaseelan V; Benson AB; Mittal RR; Dutta S; Rosen ST; Spies SM; Mettler JM; Groch MW
Cancer; 1996 Nov; 78(9):1861-70. PubMed ID: 8909304
[TBL] [Abstract][Full Text] [Related]
13. Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver: preclinical evaluation in comparison to standard chemotherapy and initial results of a phase I clinical study.
Behr TM; Salib AL; Liersch T; Béhé M; Angerstein C; Blumenthal RD; Fayyazi A; Sharkey RM; Ringe B; Becker H; Wörmann B; Hiddemann W; Goldenberg DM; Becker W
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3232s-3242s. PubMed ID: 10541369
[TBL] [Abstract][Full Text] [Related]
14. Interferon-gamma and monoclonal antibody 131I-labeled CC49: outcomes in patients with androgen-independent prostate cancer.
Slovin SF; Scher HI; Divgi CR; Reuter V; Sgouros G; Moore M; Weingard K; Pettengall R; Imbriaco M; El-Shirbiny A; Finn R; Bronstein J; Brett C; Milenic D; Dnistrian A; Shapiro L; Schlom J; Larson SM
Clin Cancer Res; 1998 Mar; 4(3):643-51. PubMed ID: 9533532
[TBL] [Abstract][Full Text] [Related]
15. Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein.
Buchsbaum DJ; Khazaeli MB; Axworthy DB; Schultz J; Chaudhuri TR; Zinn KR; Carpenter M; LoBuglio AF
Clin Cancer Res; 2005 Nov; 11(22):8180-5. PubMed ID: 16299250
[TBL] [Abstract][Full Text] [Related]
16. Radioimmunotherapy of colorectal cancer in small volume disease and in an adjuvant setting: preclinical evaluation in comparison to equitoxic chemotherapy and initial results of an ongoing phase-I/II clinical trial.
Behr TM; Memtsoudis S; Vougioukas V; Liersch T; Gratz S; Schmidt F; Lorf T; Post S; Wörmann B; Hiddemann W; Ringe B; Becker W
Anticancer Res; 1999; 19(4A):2427-32. PubMed ID: 10470170
[TBL] [Abstract][Full Text] [Related]
17. Enhanced antitumor activity of combination radioimmunotherapy (131I-labeled monoclonal antibody A33) with chemotherapy (fluorouracil).
Tschmelitsch J; Barendswaard E; Williams C; Yao TJ; Cohen AM; Old LJ; Welt S
Cancer Res; 1997 Jun; 57(11):2181-6. PubMed ID: 9187118
[TBL] [Abstract][Full Text] [Related]
18. Single-Dose versus fractionated radioimmunotherapy of human colon carcinoma xenografts using 131I-labeled multivalent CC49 single-chain fvs.
Goel A; Augustine S; Baranowska-Kortylewicz J; Colcher D; Booth BJ; Pavlinkova G; Tempero M; Batra SK
Clin Cancer Res; 2001 Jan; 7(1):175-84. PubMed ID: 11205906
[TBL] [Abstract][Full Text] [Related]
19. Prospects of radioimmunotherapy in epithelial ovarian cancer: results with iodine-131-labeled murine and humanized MN-14 anti-carcinoembryonic antigen monoclonal antibodies.
Juweid M; Swayne LC; Sharkey RM; Dunn R; Rubin AD; Herskovic T; Goldenberg DM
Gynecol Oncol; 1997 Dec; 67(3):259-71. PubMed ID: 9441773
[TBL] [Abstract][Full Text] [Related]
20. Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts.
Welt S; Divgi CR; Scott AM; Garin-Chesa P; Finn RD; Graham M; Carswell EA; Cohen A; Larson SM; Old LJ
J Clin Oncol; 1994 Jun; 12(6):1193-203. PubMed ID: 8201382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
